{
  "id": "6026c1071cb411341a0000cb",
  "type": "yesno",
  "question": "Is MK-1602 a CGRP antagonist?",
  "ideal_answer": "Yes, MK-1602 is a CGRP antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27269043"
  ],
  "snippets": [
    {
      "text": "The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA), for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial supports ubrogepant's efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}